ET-traps
ET-traps
  • ET-traps
  • ABOUT
  • TECHNOLOGY
  • ADVANTAGES
  • CLINICAL APPLICATIONS
  • INVESTORS
  • TEAM
  • NEWS
  • CONTACT
  • SCIENTIFIC PUBLICATIONS
    • ET-traps
    • ABOUT
    • TECHNOLOGY
    • ADVANTAGES
    • CLINICAL APPLICATIONS
    • INVESTORS
    • TEAM
    • NEWS
    • CONTACT
    • SCIENTIFIC PUBLICATIONS
  • ET-traps
  • ABOUT
  • TECHNOLOGY
  • ADVANTAGES
  • CLINICAL APPLICATIONS
  • INVESTORS
  • TEAM
  • NEWS
  • CONTACT
  • SCIENTIFIC PUBLICATIONS

THE UBIQUITOUS DISTRIBUTION OF ET-1 AND ITS RECEPTORS IMPLICATES ITS INVOLVEMENT IN A WIDE VARIETY OF PHYSIOLOGIC AND PATHOLOGIC PROCESSES IN THE BODY.

image492

CARDIOVASCULAR DISEASES

 Cardiovascular diseases are the number one cause of death globally and one of the costliest diseases for health care systems 

  • atherosclerosis
  • cardiac hypertrophy
  • ischemic heart disease
  • heart failure
  • stroke


CHRONIC KIDNEY DISEASE

 ~10% of the world population suffers from chronic kidney disease, majority in developing world unable to afford treatment - Every year there are ~1 million deaths from untreated kidney disease

DIABETES AND OTHER ENDOCRINE DISORDERS

Type-1  diabetes is a metabolic disorder characterized by high blood sugar levels over a prolonged period.  If left untreated, diabetes can cause many complications. Acute complications can include diabetic ketoacidosis, hyperosmolar hyperglycemic state, or death. Serious long-term complications include cardiovascular disease, stroke, chronic kidney disease, foot ulcers, and damage to the eyes.  


Currently available therapies are mainly limited to insulin and glucose control medications. However most of the fatalities and the healthcare costs related to diabetes are from complications like heart and kidney disease. ET-traps  helps bring heart and kidney function to non disease levels.


The ET-traps approach to diabetes provides therapeutic synergy for (i) bringing back the pathologically elevated levels of endothelin-1 and (ii) repair of damage caused to the vital organs (long-term complications).


Diabetes is more than just high glucose. Click here to find out more. 


We established our PoC in the Type-1 diabetes disease space. However, elevated/ pathological levels of endothelin-1 are also found in other diseases

NEURODEGENERATIVE DISORDERS

    

  • Alzheimer's disease
  • Multiple sclerosis
  • Parkinson's disease



PREGNANCY DISORDERS

Pre-eclampsia is a pregnancy-induced hypertensive disorder characterized by proteinuria and widespread maternal endothelial dysfunction. It remains one of the most common disorders in pregnancy and remains one of the leading causes of maternal and fetal morbidity. Recent research has revealed that placental insufficiency, resulting in hypoxia and ischemia, is a central causative pathway in the development of the disorder. In response, the placenta secretes soluble substances into the maternal circulation which are responsible for the symptomatic phase of the disease. Among the most well characterized factors in the disease pathology are the anti-angiogenic protein soluble fms-like tyrosine kinase-1 (sFlt-1), inflammatory cytokines, and agonistic angiotensin II type-1 receptor autoantibodies. Each of these factors has been shown to induce hypertension experimentally through the production of endothelin-1 (ET-1), a powerful vasoconstrictor. Antagonism of the endothelin-A receptor has proved beneficial in numerous animal models of gestational hypertension, and it remains an intriguing target for pharmacological intervention in pre-eclampsia.
​



Please see following link for further information on different diseases with increased levels of endothelin-1

Copyright © 2021  ET-traps  Limited- All Rights Reserved.

  • ABOUT
  • TECHNOLOGY
  • ADVANTAGES
  • CLINICAL APPLICATIONS
  • INVESTORS
  • TEAM
  • NEWS
  • CONTACT
  • SCIENTIFIC PUBLICATIONS